Roscovitine (TAK 165) is a potent EGFR and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 µM, respectively. Roscovitine (TAK 165) also inhibits p33cdk2 and p33cdk5.Roscovitine (TAK 165) displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Roscovitine (TAK 165) exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo.

June 21, 2017

prudect name : Roscovitine (TAK 165) is a potent EGFR and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 µM, respectively. Roscovitine (TAK 165) also inhibits p33cdk2 and p33cdk5.Roscovitine (TAK 165) displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Roscovitine (TAK 165) exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo.
Mubritinib (TAK 165)

Synonyms: TAK 165CAS NO: 366017-09-6Molecular Formula: C₂₅H₂₃F₃N₄O₂Molecular Weight: 468.47Purity: 98% minSolubility: In DMSOStorage: −20°C

web site: www.medchemexpress.com

References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18525027